Lupin Ltd shares receives tentative approval from U.S. FDA for Apixaban oral suspension
Why did Lupin Ltd shares fall today?
On Monday at 10:05 AM, shares of Lupin Ltd were trading at ₹2,080.25 on the BSE, reflecting a decline of 0.47% for the session. This dip in the stock price came despite a positive announcement from the company earlier in the day.
Lupin informed stock exchanges that it had received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its new drug application for an Apixaban Oral Suspension. This is a novel oral liquid formulation of the blood thinner Apixaban, developed through the 505(b)(2) regulatory pathway. The company highlighted this as a significant development in expanding its product offerings.
While the FDA approval is a long-term positive for the company's pipeline, the immediate market reaction was muted. The term "tentative approval" indicates that while the product meets required standards, there may be remaining patent or exclusivity issues before it can be commercially launched. Investors may have engaged in profit booking or reacted cautiously to this nuance, leading to the slight downward pressure on the share price during morning trade.
What does Lupin Ltd do?
Lupin Limited is a global pharmaceutical major that operates in the healthcare sector. The company is actively engaged in the development and commercialization of pharmaceutical products, as evidenced by its work on a novel Apixaban oral suspension, which has received tentative approval from the U.S. Food and Drug Administration (FDA).
The company's business involves navigating significant regulatory pathways to bring new treatments to market. Achieving tentative U.S. FDA approval for a product like an oral suspension of Apixaban indicates activity in developing formulations for key therapeutic areas, with the goal of enhancing treatment options.
Lupin Ltd Financials
In CroresLupin Ltd's revenue grew from ₹7391.91 crore in March 2026 to ₹8217.23 crore in June 2026, showing a quarter-on-quarter increase. The profit, however, saw a slight decline over the same period, moving from ₹1460.34 crore to ₹1415.0 crore.
Lupin Ltd Shareholding Pattern
Promoter holding stands at 46.85% of the total share capital. Foreign Institutional Investors (FIIs) hold 22.42% stake in the company, while Domestic Institutional Investors (DIIs) hold 24.65%. Public shareholders hold the remaining 6.08% stake in Lupin Ltd.
Lupin Ltd FAQs
Q: Why did Lupin shares fall 0.47% today?
Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Lupin Ltd?
As per the latest data, promoters hold 46.85% stake in Lupin Ltd, while FII holding stands at 22.42%. Domestic institutional investors hold 24.65%, and public shareholders account for 6.08% of the equity.
Q: What is the current stock price of Lupin Ltd?
Lupin Ltd shares are currently trading at ₹2080.25, recording a decline of 0.47% from the previous close.
Q: What is the market capitalization of Lupin Ltd?
The company currently has a market capitalization of ₹95060.76 crore, reflecting its valuation in the Indian equity market.